These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27206944)

  • 1. Prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in Brazil: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Lotufo PA; Santos RD; Figueiredo RM; Pereira AC; Mill JG; Alvim SM; Fonseca MJ; Almeida MC; Molina MC; Chor D; Schmidt MI; Ribeiro AL; Duncan BB; Bensenor IM
    J Clin Lipidol; 2016; 10(3):568-76. PubMed ID: 27206944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cholesterol concentration and prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in the Korea National Health and Nutrition Examination Surveys 2008-2010: Beyond the Tip of the Iceberg.
    Lee YH; Lee SG; Lee MH; Kim JH; Lee BW; Kang ES; Lee HC; Cha BS
    J Am Heart Assoc; 2014 Feb; 3(1):e000650. PubMed ID: 24572249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Feb; 60(4):109-14. PubMed ID: 21293326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia according to gender and race: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Santos RD; Bensenor IM; Pereira AC; Lotufo PA
    J Clin Lipidol; 2016; 10(6):1362-1368. PubMed ID: 27919353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults.
    Hyre AD; Muntner P; Menke A; Raggi P; He J
    Ann Epidemiol; 2007 Jul; 17(7):548-55. PubMed ID: 17395483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004.
    Upadhyay UD; Waddell EN; Young S; Kerker BD; Berger M; Matte T; Angell SY
    Prev Chronic Dis; 2010 May; 7(3):A61. PubMed ID: 20394700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.
    Diamantopoulos EJ; Athyros VG; Yfanti GK; Migdalis EN; Elisaf M; Vardas PE; Manolis AS; Karamitsos DT; Ganotakis ES; Hatseras D;
    Angiology; 2005; 56(6):731-41. PubMed ID: 16327950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil.
    Harada PH; Miname MH; Benseñor IM; Santos RD; Lotufo PA
    Atherosclerosis; 2018 Oct; 277():273-277. PubMed ID: 30270058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006.
    Kuklina EV; Yoon PW; Keenan NL
    JAMA; 2009 Nov; 302(19):2104-10. PubMed ID: 19920234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and control of hypercholesterolaemia as defined by NCEP-ATPIII guidelines and predictors of LDL-C goal attainment in a multi-ethnic Asian population.
    Khoo CM; Tan ML; Wu Y; Wai DC; Subramaniam T; Tai ES; Lee J
    Ann Acad Med Singap; 2013 Aug; 42(8):379-87. PubMed ID: 24045373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.